High-dose chemotherapy for solid tumors: results of the EBMT.

The European Group for Blood and Marrow Transplantation (EBMT), formerly known as European Group for Bone Marrow Transplantation, was established in 1974 in the Netherlands to share experiences, to promote research and clinical studies and to set up registries in the field of hematopoietic tissue transplantation. At the present time more 400 European and non-European centers are members of the EBMT group. In 1984 a new Working Party was created (Solid Tumors) with the aim to investigate the role of high-dose chemotherapy and stem cell support in the fields of adult and pediatric solid tumors. By January 2000 more than 14000 patients were registered, and at the present time this Registry is the world largest database on this subject. Several phase III randomized clinical trials have recently started on behalf of the Group in different diseases (breast carcinoma, small cell lung cancer, ovarian carcinoma, germ cell tumors and Ewing's family sarcoma). Hundreds of randomized patients will finally produce clearer information on this still experimental therapeutic modality. This paper will describe the EBMT Solid Tumors Working Party Registry updated results as well as the main ongoing studies.

[1]  M. Marangolo,et al.  Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  N. Schmitz,et al.  Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998 , 1998, Bone Marrow Transplantation.

[3]  D. Frappaz,et al.  Impact of megatherapy on survival after relapse from stage 4 neuroblastoma in patients over 1 year of age at diagnosis: a report from the European Group for Bone Marrow Transplantation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Hortobagyi,et al.  Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Armitage,et al.  Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. , 1999, JAMA.

[6]  R. Motzer,et al.  Testicular germ-cell cancer. , 1997, The New England journal of medicine.

[7]  J. Peterse,et al.  Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement , 1998, The Lancet.

[8]  Terry L. Smith,et al.  Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. , 2000, Journal of the National Cancer Institute.

[9]  R. Theriault,et al.  High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study , 2000, The Lancet.

[10]  A Kramar,et al.  High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Smith,et al.  High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Dose and timing : the pillars of successful chemotherapy , 1998 .

[13]  A. Luini,et al.  Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Gratwohl,et al.  Blood and marrow transplantation activity in Europe 1995 , 1997, Bone Marrow Transplantation.

[15]  L. Seymour,et al.  High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  W. Bezwoda Randomised controlled trial of high dose chemotherapy (HD-CNVp) versus standard dose (CAF) chemotherapy for high risk, surgically treated, primary breast cancer , 1999 .

[17]  T. Klingebiel,et al.  1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party. , 1997, European journal of cancer.

[18]  A. Gratwohl,et al.  Blood and marrow transplantation activity in Europe 1997 , 1999, Bone Marrow Transplantation.

[19]  A. Gratwohl,et al.  Hematopoietic precursor cell transplants in Europe: activity in 1994. Report from the European Group for Blood and Marrow Transplantation (EBMT). , 1996, Bone marrow transplantation.

[20]  G. Bonadonna,et al.  Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  P. Richardson,et al.  Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Armitage,et al.  Reviews and Notes: Oncology: High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells , 1992, Annals of Internal Medicine.

[23]  J. Machiels,et al.  Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  G. Hortobagyi,et al.  High-Dose Chemotherapy in Breast Cancer , 1991 .

[25]  S. Martino,et al.  Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. , 2000, The New England journal of medicine.

[26]  R. Storb,et al.  Mini-allografts: ongoing trials in humans , 2000, Bone Marrow Transplantation.

[27]  J. Armitage,et al.  High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  C. Gisselbrecht,et al.  Dose intensive therapy in breast cancer. , 1992, Bone marrow transplantation.

[29]  G. Rosner,et al.  High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.